Boston Scientific Corporation's new Guidant unit is facing about 300 class-action and individual lawsuits related to problems with Guidant heart devices that became public last year, Boston Scientific disclosed in a regulatory filing Wednesday. The lawsuit tally includes about 66 product-liability class-action suits and about 234 individual suits, Boston Scientific said in its quarterly filing with the Securities and Exchange Commission. The total number of lawsuits has grown by nearly 100 since Guidant last released a tally in late February. Guidant's cardiac rhythm management division is based in Arden Hills.
The
Star Tribune
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Biom’up’s Laparoscopic Applicator Earns New Marketing Approval
The device quickly delivers Hemoblast powder to bleeding areas in minimally-invasive surgeries.
Lawmakers Want Probe of BMS/Celgene Deal
The cancer drugs the company will acquire as part of the deal include Celgene’s blockbuster drug Revlimid.
FDAnews Device Daily Bulletin
GUIDANT LAWSUITS AT 300, BOSTON SCI SAYS
May 12, 2006
